Ptychopetalum olacoides, a traditional Amazonian “nerve tonic”, possesses anticholinesterase activity
Introduction
Cognitive impairment during normal aging as well as in the Alzheimer's disease (AD) is thought to be associated to the degeneration of the basal forebrain cholinergic neurons. The aging rat is a well-established model of spontaneous brain cholinergic hypoactivity, useful to study the effects of drugs on the cholinergic transmission, as well as on age-associated cognitive impairment (Quirion et al., 1995). Accordingly, transgenic mice overexpressing human acetylcholinesterase (AChE) in brain neurons have cognitive deterioration, corroborating the role of this system in the modulation of spatial memory Andres et al., 1996, Beeri et al., 1995. In addition, brain cholinergic deficits, especially in the neocortex, amygdala and hippocampus are important neuropathologic findings in AD patients (Cummings and Back, 1998), usually accompanying abnormal components of the neuronal cytoskeleton, such as tangles and β-amyloid senile plaques (Vickers et al., 2000). The cholinergic hypothesis of Alzheimer disease (AD) has provided the rationale for the current pharmacotherapy of this disease, in an attempt to downgrade the cognitive decline caused by cholinergic deficits. Among the possible strategies for enhancing brain cholinergic activity, acetylcholinesterase inhibitors (AChEIs) have been the most extensively used for the symptomatic treatment of AD. Physostigmine and tacrine are the only AChEIs reasonably evaluated in AD patients, even though their use is limited by the short half-life and peripheral cholinergic side effects of physostigmine, and the dose-dependent hepatotoxicity of tacrine Nordberg and Svensson, 1998, Watkins et al., 1994, Yoshida and Suzuki, 1993. While newer AChE inhibitors, such as donepezil and huperazine, have been recently introduced in the European market Rogers and Friedhoff, 1996, Sugimoto et al., 1992, the identification of a potent long-acting AChE inhibitor with fewer side effects in AD patients would be highly advantageous.
Brazil houses an enormous biological and cultural diversity, with several medicinal plants identified by local peoples as being useful for treating CNS disorders. Within the context of drug development, the interest in traditional medical systems has been mostly focused on its plant-based remedies, with the underlying understanding that some species may contain therapeutically useful compounds Abelson, 1990, Cragg and Newman, 2001. Ptychopetalum olacoides Bentham (PO, Olacaceae), known as “Marapuama” (and/or Muirapuama and Mirantã among others) is widely consumed throughout the Amazon region. Local communities use PO-based alcoholic infusions for the treatment of CNS-related ailments and/or during highly stressful periods Elisabetsky, 1987, Grenand et al., 1987, Siqueira et al., 1998, Steinmetz, 1962. The frequencies of elders amongst users, and by patients recovering from conditions associated with damage to the central nervous system (such as stroke), are of particular interest (Elisabetsky and Siqueira, 1998). It is noteworthy that PO has nowadays been included in dozens of herbal drugs or multivitamin dietary supplements at the international market, based on claims of enhanced physical and cognitive performance.
Recognizing the value of traditional knowledge, and the various CNS activities identified with an ethanol extract obtained from PO roots Siqueira et al., 1998, da Silva et al., 2002a, including the enhancement of memory retrieval in young and aged mice (da Silva et al., 2002b), the purpose of this study was to evaluate the effects of POEE on AChE activity.
Section snippets
Plant material
Roots of P. olacoides Bentham (PO, Olacaceae) were collected at the State of Pará (Brazil), and identified by Mr. Nelson Rosa (voucher deposited at the Goeldi Museum herbarium, MG 108036).
The plant species was further authenticated through quantitative analysis for lupeol in the roots using the method described by Auterhoff and Momberger (1971); we found an average lupeol yield of 0.28% in the roots, in accordance with the data published by these authors for this species.
Ethanol extract
The extractive
Results
No significant differences in AChE activity (dA/min) were found with phosphate buffer (data not shown) or DMSO over time; the absolute mean(±S.D.) dA/min for DMSO control groups were 0.0050(0.0011), 0.0054(0.0003) and 0.0056(0.0006) for frontal cortex, 0.0040(0.0005), 0.0039(0.0006) and 0.0041(0.0003) for hippocampus, and 0.0047(0.0004), 0.0049(0.0004) and 0.0051(0.0005) for striatum at 15, 30 and 60 min, respectively.
POEE significantly inhibited in vitro AChE activity, in a dose- and
Discussion
It is now widely accepted that hypoactivity of the cholinergic system plays a central role in cognitive deficits De Lacalle et al., 1996, Quirion et al., 1995, Taylor and Griffith, 1993. Accordingly, despite serious limitations in both efficacy and adverse effects, inhibition of AChE is the current basis for drug therapy in AD Rogers and Friedhoff, 1996, Sugimoto et al., 1992, Watkins et al., 1994.
We have recently found that P. olacoides ethanol extract (POEE) improved long-term memory
Acknowledgements
We gratefully acknowledge financial support received from FINEP/PRONEX, FAPERGS, CAPES, CNPq and PROPESQ-UFRGS. There is a patent request (PI0205432-9, INPI, Brazil) associated with this study.
References (37)
- et al.
Cholinergic drug resistance and impaired spatial learning in transgenic mice overexpressing human brain acetylcholinesterase
Prog. Brain Res.
(1996) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein–dye binding
Anal. Biochem.
(1976)- et al.
Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities
Pharmacol. Biochem. Behav.
(1998) - et al.
General occurrence of binding to acetylcholinesterase-substrate complex in noncompetitive inhibition and in inhibition by substrate
Biochim. Biophys. Acta
(1991) - et al.
The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease
Am. J. Geriatr. Psychiatry
(1998) - et al.
Reduced retrograde labelling with fluorescent tracer accompanies neuronal atrophy of basal forebrain cholinergic neurons in aged rats
Neuroscience
(1996) - et al.
A new and rapid colorimetric determination of acetylcholinesterase activity
Biochem. Pharmacol.
(1961) - et al.
Potencies and stereoselectivities of enantiomers of huperzine A for inhibition of rat cortical acetylcholinesterase
Eur. J. Pharmacol.
(1991) - et al.
Atypical effect of some spin trapping agents: reversible inhibition of acetylcholinesterase
Free Radic. Biol. Med.
(2000) - et al.
A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcolinesterase inhibitors tacrine, donepezil and NXX-066
Neuropharmacology
(1999)